Atlas Trials

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Clinical trial NCT04611880 · COMPLETED

Trial details

NCT number
NCT04611880
Sponsor
Washington University School of Medicine
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Start date
2021-01-25
Primary completion
2025-04-02
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.